Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21, 2020
The Center for Biosimilars
On July 21, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.
Click here to access the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
Axinn Antitrust Insight: HSR Overhaul: Out with the New, In with the Old
Axinn Viewpoints
Antitrust
The DOJ's Whistleblower Program and Leniency
Axinn Viewpoints
Antitrust
Squires Again Broadens Discretion for Post-Grant Proceedings
Axinn Viewpoints
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity
Axinn Viewpoints
Intellectual Property
Mother, May I? The Use of Prior Approval Requirements in Merger Settlements
Podcast
Antitrust
The Curtain Rises Again on FTC Act Section 5
Axinn Viewpoints
